Jakarta, Indonesia – April 25, 2024
In a landmark move set to redefine the future of healthcare in Indonesia, Thermo Fisher Scientific and Mandaya Hospital Group have officially signed a Memorandum of Understanding (MOU) to collaborate on the development of advanced cell and gene therapies. The MOU, signed on April 24th, 2024, represents a significant commitment by both parties to enhance therapeutic options for patients through innovative biomedical solutions.
Under this collaboration, Mandaya Hospital Group, through its affiliate company PT Regenera Biomedik, will spearhead the manufacturing of cutting-edge therapeutic products under the brand name TheraCellix. The focus will be on producing Mesenchymal Stem Cells, Secretome, and Exosome-based therapies, which hold the promise of transforming regenerative medicine by offering personalized and targeted treatment options.
Furthermore, TheraCellix will also embark on the manufacturing of CAR-T Cells, an innovative and highly effective form of immunotherapy designed to combat cancer. CAR-T therapy involves genetically modifying a patient’s own T-cells to better recognize and destroy cancer cells, offering new hope to those with difficult-to-treat malignancies.
Dr. Ben Widaja, MBChB, President Director of Mandaya Hospital Group, remarked, “The signing of this MOU marks a pivotal moment in our journey to bring world-class healthcare innovations to Indonesia. Through our collaboration with Thermo Fisher Scientific, TheraCellix will be at the forefront of producing advanced therapies that can significantly improve patient outcomes, especially in the areas of regenerative medicine and cancer treatment.“
Thermo Fisher Scientific, a global leader in serving science, will provide the necessary technological expertise and support to ensure the success of these ambitious projects. Their role will be crucial in equipping PT Regenera Biomedik with the tools and knowledge required to manufacture these complex biological therapies to the highest standards.
The signing ceremony, which took place earlier this year, was attended by senior executives from both organizations, symbolizing a shared commitment to pushing the boundaries of what is possible in medical science. This partnership is expected to fast-track the availability of these therapies in Indonesia, making cutting-edge treatments accessible to a broader patient population.
This collaboration between Thermo Fisher Scientific and Mandaya Hospital Group underscores the growing importance of cell and gene therapies in the global healthcare landscape. As TheraCellix begins its work in manufacturing Mesenchymal Stem Cells, Secretome, Exosomes, and CAR-T Cells, the partnership is poised to set new benchmarks for medical treatment in Indonesia and beyond.
About Mandaya Hospital Group
Mandaya Hospital Group is a premier healthcare provider in Indonesia, known for its commitment to delivering high-quality patient care and driving medical innovation. Through PT Regenera Biomedik, the group is leading the development of advanced cell and gene therapies under the TheraCellix brand.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with a mission to enable customers to make the world healthier, cleaner, and safer. With an unmatched portfolio of innovative technologies, Thermo Fisher Scientific is a trusted partner in the life sciences industry.